You are Trying to View a Free Article

Daily News You Can't Find Anywhere Else

BMS to Buy Celgene in Deal Worth $74 Billion, an Industrial Info Market Brief

pharmaceutical

Industry Segment: Pharmaceutical & Biotech | Word Count: 83 Words

Pharma-bio giants Bristol-Myers Squibb Company (NYSE:BMY) (BMS) and Celgene Corporation (NASDAQ:CELG) have announced that they have entered into a definitive merger agreement in which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of about $74 billion.

Benefits of the merger range from highly complementary portfolios, with leading franchises in oncology, immunology and inflammation and cardiovascular disease, to about $2.5 billion of expected run-rate cost synergies to be achieved by 2022, according to the companies.

Subscribe Now! All Fields Required...

Standard Membership - Free